公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!

抑制剂描述:

产品名称:1-((3aS,4R,9bR)-4-(6-溴苯并[d][1,3]二氧代l-5-基)-3a,4,5,9b-四氢-3H-环戊并[c]喹啉-8-基)乙酮

产品别名:见爱必信官网

英文别名:1-((3aS,4R,9bR)-4-(6-溴苯并[d][1,3]二氧代l-5-基)-3a,4,5,9b-四氢-3H-环戊并[c]喹啉-8-基)乙酮

靶点:

CAS:881639-98-1

纯度:≥98%

外观:见爱必信官网

保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

描述:

GPR30 is a transmembrane G protein-coupled receptor (GPCR) localized to endoplasmic reticulum (ER) that binds estradiol with high affinity, activating multiple intracellular signaling pathways. G-1 is a nonsteroidal, high-affinity, selective agonist of GPR30 that binds with a K_i value of 11 nM. Competitive binding studies in endoplasmic reticulum α- (ERα-) and ERβ-expressing cells yielded K_i values for estradiol of 0.30 and 0.38 nM, respectively, with no substantial binding of G-1 at 1 µM. The discovery of G-1, a compound that does not bind classical ERs, should facilitate further physiological experiments to define the role of GPR30 in vivo.

溶解性:DMSO : 50 mg/mL (121.28 mM; Need ultrasonic)

体外研究:

G-1 is a nonsteroidal, high-affinity and selective agonist of GPR30 with a Ki of 11 nM. Treatment with G-1 (10 μM and 100 μM) for 48 and 72 h significantly decreases cell proliferation (P<0.001). At 72 h, the IC50 value for G-1 is calculated to be 20 μM. Treatment of A549 cells with G-1 at a concentration of 20 μM reveals a significant increase in apoptosis, consistent with its antiproliferative effect (P<0.001). Cell cycle analysis of H295R cells after 24 h of G-1 treatment demonstrates a cell cycle arrest in the G2 phase. The presence of G-1 increases Bax expression while decreases Bcl-2.

体内研究:The results at 14 days post-injury show that the Basso mouse scale (BMS) scores are significantly higher in the G-1 group compared with the other groups (P<0.05). The number of caspase-3-positive cells in the cross sections is counted, and G-1 group has fewer positive cells compare with the other groups (P<0.05), and there is no difference between the two groups (P>0.05). G-1 administration produces a statistically significant decrease in tumor volume from day 14 post treatment. Grafted tumors harvested after three-week treatment with G-1 show a significant decrease in tumor weight compare to vehicle treated animals.

产品信息订购:

产品更多信息请进入爱必信网站咨询